– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 – – Achieved $75 million milestone payment from Vertex for the clinical advancement of its Phase 1/2 clinical trial of VX-670 for DM1 – – Cash runway expected through the second quarter of 2026 with $327 million in cash, cash equivalents and marketable securities as of March 31, 2024 – BOSTON, May 07, 2024 (GLOBE NEWSWIRE) --
Director Peter Kim of Entrada Therapeutics Inc (NASDAQ:TRDA) has recently increased his stake in the company.
The analysts covering Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) delivered a dose of negativity to shareholders today...